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Background:  MicroRNAs (miRs) are small non-coding molecules that regulate gene expression. MiRs 
expression levels change not only in diseased tissues but also in circulation. Further, miRs are stable in 
frozen samples that make them attractive for biomarker discovery. Recent reports suggest altered 
expression of circulating miRNAs in various diseases. MiR-122 is highly abundant in hepatocytes where it 
regulates different metabolic pathways while miR-155 is a central regulator of inflammation. The aim of 
this study
 
 was to evaluate circulating miRNAs as potential markers of hepatocyte damage and 
inflammation in liver diseases.   
Methods
 
:  Serum/plasma and liver samples were collected from C57/BL6 mice after: 1. Chronic alcohol 
feeding with Lieber-deCarli diet containing alcohol or pair-fed diet for 5 weeks 2. Acetaminophen (APAP) 
administration. 3. TLR9/4 administration. 4. CCL4 administration. Serum/plasma ALT was evaluated and 
total RNA was analyzed for miRNAs expression with TaqMan MicroRNA assay. Non-parametric Mann-
Whitney test was used for statistics. 
Results
 
:  The alcohol, APAP, TLR9/TLR4 and CCL4, -induced liver injury models all resulted in ALT 
increase and more important, in increased serum/plasma miR-122 levels compared to control mice. 
There was a linear correlation between miR-122 and ALT levels. After CCL4 treatment, serum miR-122 
was upregulated as early as one week over controls and it remained elevated. No increase in serum miR-
122 in Toll like receptor 4 or NADPH oxidase–deficient mice was found after alcohol feeding as these KO 
mice were protected from alcohol-induced liver injury and inflammation. Alcohol-, APAP, TLR9/TLR4 and 
CCL4-induced liver damage all involve in activation of the inflammatory cascade. Consistent with this, 
we found increased serum miR-155 levels.  
Conclusion:  Our novel results show that serum/plasma miR-122 up-regulation correlates with ALT, thus, 
miR-122 could be a useful biomarker in acute and chronic liver injury. We also report that serum miR-
155 is increased in liver disease with inflammation. 
